

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
10 February 2005 (10.02.2005)

PCT

(10) International Publication Number  
**WO 2005/011653 A3**

(51) International Patent Classification<sup>7</sup>: **C07D 237/20**,  
237/22, A61K 31/501, A61P 3/06

(21) International Application Number:  
PCT/US2004/024541

(22) International Filing Date: 29 July 2004 (29.07.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/491,116 30 July 2003 (30.07.2003) US  
60/491,095 30 July 2003 (30.07.2003) US

(71) Applicant (for all designated States except US): **XENON  
PHARMACEUTICALS INC.** [CA/CA]; 3650 Gilmore  
Way, Burnaby, British Columbia V5G 4W8 (CA).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **GSCHWEND**,  
Heinz, W. [US/US]; 161 Meadowcroft Way, Santa  
Rosa, CA 95403 (US). **KODUMURU**, Vishnumurthy  
[CA/CA]; 211-6577 Royal Oak Avenue, Burnaby, British  
Columbia V5H 3P3 (CA). **LIU**, Shifeng [CA/CA];  
15-2615 Fortress Drive, Port Coquitlam, British Columbia  
V3C 6E8 (CA). **KAMBOJ**, Rajender [CA/CA]; 5809  
Sperling Avenue, Burnaby, British Columbia V5E 2T6  
(CA).

(74) Agents: **ROTH**, Carol, J. et al.; Seed Intellectual Property  
Law Group PLLC, Suite 6300, 701 Fifth Avenue, Seattle,  
WA 98104-7092 (US).

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,  
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,  
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,  
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,  
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,  
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,  
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,  
ZW.

(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, GH,  
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,  
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,  
FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,  
SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,  
GW, ML, MR, NE, SN, TD, TG).

**Declaration under Rule 4.17:**

— of inventorship (Rule 4.17(iv)) for US only


**Published:**

— with international search report  
— before the expiration of the time limit for amending the  
claims and to be republished in the event of receipt of  
amendments

(88) Date of publication of the international search report:  
14 April 2005

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(54) Title: PYRIDAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS



(57) Abstract: Methods of treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the methods comprise administering to a mammal in need thereof a compound of formula (I): where x, y, W, V, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>6a</sup>, R<sup>7</sup>, R<sup>7a</sup>, R<sup>8</sup>, R<sup>8a</sup>, R<sup>9</sup> and R<sup>9a</sup> are defined herein. Pharmaceutical compositions comprising the compounds of formula (I) are also disclosed.